Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

25.32 -0.09 (-0.33%)
Streaming Delayed Price Updated: 10:25 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Is SoundHound AI a Millionaire-Maker Stock? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
News headline image
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids ↗
 
Via Benzinga
News headline image
Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report ↗
The company also raised its outlook for the year. 
Via Investor's Business Daily
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today ↗
 
Via Benzinga
News headline image
A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus ↗
 
Via Benzinga
News headline image
Teva to Present at the Jefferies London Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript ↗
TEVA earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast ↗
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion. 
Via Benzinga
News headline image
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Statement on European Commission Decision; Company to Appeal
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes ↗
Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud... 
Via Benzinga
Topics Fraud
News headline image
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected ↗
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
News headline image
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
From Teva Pharmaceutical Industries Ltd; mAbxience
Via GlobeNewswire
News headline image
Teva Launches Generic Version Of Sandostatin In The US ↗
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know. 
Via Benzinga
News headline image
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast ↗
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the... 
Via Benzinga
News headline image
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
News headline image
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.